Detection and significance of LCN2 and PDGF-BB in serum and metastasis of lung cancer patients with bone metastasis
10.13315/j.cnki.cjcep.2019.02.014
- VernacularTitle:肺癌骨转移患者血清和转移灶中LCN2和PDGF-BB的检测及意义
- Author:
Ya-Nan CAO
1
;
Jing-Jing LI
;
Hang ZHANG
;
Cong GAO
;
Xiang DONG
;
Peng-Fei REN
;
Chen-Xu MENG
;
Fan-Fan LI
Author Information
1. 安徽医科大学第二附属医院肿瘤科
- Keywords:
lung neoplasms;
non-small-cell lung;
secondary;
lipocalin 2;
platelet derived growth factor-BB
- From:
Chinese Journal of Clinical and Experimental Pathology
2019;35(2):187-191
- CountryChina
- Language:Chinese
-
Abstract:
Purpose To investigate the expression of lipocalin-2 (LCN2) and plateled derived growth factor-BB (PDGF-BB) in serum,carcinoma and bone metastases of lung cancer patients. Methods Protein chip were used to screen the differential expression of cytokines in serum of 19 lung cancer patients (9 patients with bone metastasis and 10 patients freedistant metastasis) . Immunohistochemistry was performed to assess the differential expression of LCN2 and PDGF-BB cytokines in 12 cases of primary lung cancer without distant metastasis and 12 cases of primary lung cancer with only bone metastasis. Results Serum level of lipid transport factor (LCN2) and PDGFBB in non-small cell lung cancer patients with bone metastasis were significantly higher than that without distant metastasis(P< 0. 05) . There was no difference cytokines between small cell lung cancer patients with bone metastasis and without metastasis group (P > 0. 05) . The results of immunohistochemistry showed that high expression of LCN2 and PDGF-BB in bone metastasis tissues was significantly higher than that in primary lung cancer tissues. Conclusions High expression of LCN2 and PDGF-BB in serum and bone metastasis tissue of patients with non-small cell lung cancer might be involved in the occurrence,development of bone metastasis of lung cancer in the bone marrow,may be an important biomarker and potential therapeutic target for bone metastasis of lung cancer.
